MX393043B - Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos - Google Patents

Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos

Info

Publication number
MX393043B
MX393043B MX2021007569A MX2021007569A MX393043B MX 393043 B MX393043 B MX 393043B MX 2021007569 A MX2021007569 A MX 2021007569A MX 2021007569 A MX2021007569 A MX 2021007569A MX 393043 B MX393043 B MX 393043B
Authority
MX
Mexico
Prior art keywords
tetrahydrouridine
azacitidine
compositions containing
decitabine
containing decitabine
Prior art date
Application number
MX2021007569A
Other languages
English (en)
Other versions
MX2021007569A (es
Inventor
Henry Lau
Joseph Desimone
Santhosh Vadivelu
Yogen Saunthararajah
Original Assignee
Epidestiny Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidestiny Inc filed Critical Epidestiny Inc
Publication of MX2021007569A publication Critical patent/MX2021007569A/es
Publication of MX393043B publication Critical patent/MX393043B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones que comprenden decitabina y tetrahidrouridina o 5-azacitidina y tetrahidrouridina para el tratamiento del cáncer. Las composiciones en forma de píldora se administran a un sujeto humano en secuencia o de manera alternada en función de la medición de biomarcadores predictivos.
MX2021007569A 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos MX393043B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262839P 2015-12-03 2015-12-03
US201662429292P 2016-12-02 2016-12-02
PCT/US2016/064935 WO2017096357A1 (en) 2015-12-03 2016-12-05 Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof

Publications (2)

Publication Number Publication Date
MX2021007569A MX2021007569A (es) 2022-06-09
MX393043B true MX393043B (es) 2025-03-24

Family

ID=58798100

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018006790A MX383757B (es) 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos
MX2021007569A MX393043B (es) 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018006790A MX383757B (es) 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos

Country Status (9)

Country Link
US (3) US11376270B2 (es)
EP (2) EP3960182B1 (es)
JP (2) JP7194021B2 (es)
CN (1) CN109789155B (es)
BR (1) BR112018011324A2 (es)
CA (1) CA3007357C (es)
DK (2) DK3960182T3 (es)
MX (2) MX383757B (es)
WO (1) WO2017096357A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976054A4 (en) * 2019-05-24 2023-10-04 The Cleveland Clinic Foundation TIMED ADMINISTRATION OF DECITABINE AND 5-AZACYTIDINE FOR CANCER TREATMENT
US20210077492A1 (en) * 2019-09-17 2021-03-18 The Trustees Of Indiana University Methods and compositions of treating pancreatic cancer
WO2021211890A1 (en) * 2020-04-16 2021-10-21 Adimabio Llc Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
WO2000051639A2 (en) 1999-03-01 2000-09-08 Halogenetics, Inc. Treatment of neoplastic diseases by radiation
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050056280A1 (en) 2002-12-31 2005-03-17 Nektar Therapeutics Receptacle for an aerosolizable pharmaceutical formulation
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
CA2617611A1 (en) 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
US8399420B2 (en) 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
EP2050757A1 (en) 2007-10-10 2009-04-22 Cilag AG Method of producing 2' -deoxy-5-azacytidine (Decitabine)
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
AU2009246926B2 (en) 2008-05-15 2014-06-26 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2381780B1 (en) 2008-12-22 2015-02-25 Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
US9265785B2 (en) * 2008-12-22 2016-02-23 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
WO2010093435A1 (en) 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8329666B2 (en) 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
CA2757745C (en) 2009-04-06 2018-02-13 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
CN102485232A (zh) 2010-12-06 2012-06-06 苏州科耐尔医药科技有限公司 一种含地西他滨的药物组合物
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
US8426143B2 (en) 2011-05-24 2013-04-23 Saladax Biomedical Inc. Gemcitabine immunoassay
WO2014025582A1 (en) 2012-08-10 2014-02-13 Trustees Of Dartmouth College Method and kit for determining sensitivity to decitabine treatment
US20140100182A1 (en) 2012-10-05 2014-04-10 The Cleveland Clinic Foundation Nanogel-Mediated Drug Delivery
WO2014143051A1 (en) 2013-03-15 2014-09-18 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer

Also Published As

Publication number Publication date
EP3383406A1 (en) 2018-10-10
CN109789155A (zh) 2019-05-21
JP2018538370A (ja) 2018-12-27
EP3960182A1 (en) 2022-03-02
MX383757B (es) 2025-03-04
US20220152075A1 (en) 2022-05-19
CA3007357A1 (en) 2017-06-08
US11376270B2 (en) 2022-07-05
CA3007357C (en) 2023-12-05
US11779591B2 (en) 2023-10-10
BR112018011324A2 (pt) 2018-12-04
US20200246368A1 (en) 2020-08-06
DK3960182T3 (da) 2025-04-07
MX2018006790A (es) 2019-05-02
DK3383406T3 (da) 2022-01-10
US20240165142A1 (en) 2024-05-23
JP7194021B2 (ja) 2022-12-21
EP3383406A4 (en) 2019-08-21
JP2022184941A (ja) 2022-12-13
MX2021007569A (es) 2022-06-09
CN109789155B (zh) 2025-02-07
EP3383406B1 (en) 2021-10-20
WO2017096357A1 (en) 2017-06-08
EP3960182B1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
IL257379A (en) Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex
MX2020009154A (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
HUE057660T2 (hu) Multimodális terápiás sejtrendszerekkel kapcsolatos készítmények és eljárások rákindikációkra
DK3294770T4 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
UY36701A (es) Tratamiento contra el cáncer por manipulación de la microflora comensal
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
AR105433A1 (es) Métodos para mejorar la eficacia y expansión de las células inmunes
SI3198033T1 (sl) Uporaba panelov FGRF-mutantnih genov pri identificiranju rakavih pacientov, ki bodo odzivni na zdravljenje z zaviralcem FGRF
ECSP17043316A (es) Polvo de coleópteros
CR20150648A (es) Derivados de nucleósido 4´-azido, 3´-desoxi-3´-fluoro sustituido
ECSP17003946A (es) Anticuerpos antagonistas del interferón alfa y omega
UY35399A (es) Conjugados de fármacos con anticuerpos
LT3265102T (lt) Beta-d-2'-deoksi-2'alfa-fluor-2'-beta-c-pakeistieji-2-modifikuoti-n6- pakeistieji purino nukleotidai, skirti hcv gydymui
EP3706753A4 (en) ADENOSINE PATHWAY INHIBITORS FOR CANCER TREATMENT
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
MX2023006416A (es) Anticuerpos, usos y metodos.
IL263845B (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
MX393043B (es) Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos
CL2015002531A1 (es) Anticuerpos contra quimiocinas cxc pan-elr+
CR20150649A (es) Derivados de nucleósidos 4´-azido,3´-desoxi-3´-fluoro sustituido
EP3331518A4 (en) COMBINATION THERAPY WITH ACAMPROSATE AND D-CYCLOSERIN
MX374378B (es) Mioinositol y probioticos, y uso de estos.